The drug is a mixture of two antibodies, manufactured versions of proteins that are typically produced as part of an immune response to a virus, according to Bloomberg.
Regeneron plans to study the drug in humans for the first time in June.
Other drugmakers are also developing antibody drugs for COVID-19, including Eli Lilly, AstraZeneca and Vir Biotechnology.
Read the full article here.
More articles on pharmacy:
FDA clarifies relaxed compounding rules for pharmacies
Gilead gets FDA emergency use authorization for remdesivir
AmerisourceBergen offers to buy Walgreens’ drug wholesaling division
